Trial Updates and Public Offering - Research Report on Gilead, Celgene, Ariad ... PR Newswire (press release) Gilead reported that the safety profile of idelalisib was acceptable and consistent with prior experience in combination with rituximab in previously treated CLL. The Full Research Report on Gilead Sciences Inc. - including full detailed breakdown ... |
